Evidence map›Paper›PMID 42713064›Full record

SynthesisFrontiers in neurology2026

Middle meningeal artery embolization for chronic subdural hematoma: Interpreting divergent randomized evidence and guiding patient selection.

Dongfang Yang, Haibin Zhang, Ji Xia, Baoling Liu, Mei Li

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dongfang Yang *The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai, China.
Haibin Zhang *The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Ji XiaCentral Hospital of Dalian University of Technology (Dalian Municipal Central Hospital), Dalian, China.
Baoling LiuCentral Hospital of Dalian University of Technology (Dalian Municipal Central Hospital), Dalian, China.
Mei LiCentral Hospital of Dalian University of Technology (Dalian Municipal Central Hospital), Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic subdural hematoma (cSDH) is among the most common neurosurgical conditions in adults, with incidence rising steadily in aging populations and with increasing antithrombotic drug use. Burr-hole drainage remains the standard treatment for symptomatic cSDH; however, postoperative recurrence rates range from 8 to 30%. Middle meningeal artery embolization (MMAE) targets the pathological blood supply of the dural neomembrane, intervening at the biological source of hematoma progression and representing a fundamental shift in cSDH management. Between 2024 and 2025, four landmark randomized controlled trials (RCTs)-EMBOLISE, STEM, MAGIC-MT, and EMPROTECT-were published. Their conclusions diverge: EMBOLISE and STEM demonstrated that MMAE significantly reduced treatment failure, whereas MAGIC-MT (

Indexed as

Embolization, TherapeuticHematoma, Subdural, ChronicMeningeal ArteriesPatient SelectionHumansRandomized Controlled Trials as Topicchronic subdural hematomaclinical indicationscomplicationsembolic materialsevidence synthesismiddle meningeal artery embolizationpatient selection

Identifiers

PMID42713064
PMCPMC13552007

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.